Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Suizhi Gao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5130-0327; OpenAlex author ID A5055712059. Sources: OpenAlex.

Their work

Papers
30 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2019: 4 papers · 2020: 3 papers · 2021: 5 papers · 2022: 4 papers · 2023: 5 papers · 2024: 1 paper · 2025: 6 papers · 2026: 2 papers

Papers 30

  1. ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer. Co-author DOI 10.1016/j.isci.2026.117479↗
  2. T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial. Co-author DOI 10.1016/j.ymthe.2026.03.012↗
  3. Periarterial divestment following neoadjuvant therapy in patients with locally advanced pancreatic cancer with celiac axis invasion: A safe and effective surgi… Co-author DOI 10.1016/j.surg.2024.109045↗
  4. A practical distribution pattern of α-SMA-positive carcinoma associated fibroblasts indicates poor prognosis of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2025.102282↗
  5. Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. Co-author DOI 10.1038/s41467-025-57520-3↗
  6. Germline mutations and pancreatic cancer risk in chronic pancreatitis. First author DOI 10.1136/gutjnl-2024-334277↗
  7. Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. Co-author DOI 10.1172/jci.insight.181873↗
  8. Senescence-driven molecular subtyping in pancreatic cancer: a multi-omics framework for precision medicine. Co-author DOI 10.1186/s12885-025-15341-z↗
  9. Circulating cell-free DNA methylation-based multi-omics analysis allows early diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/1878-0261.13643↗
  10. Risk factors of positive resection margin differ in pancreaticoduodenectomy and distal pancreatosplenectomy for pancreatic ductal adenocarcinoma undergoing upf… Co-author DOI 10.1016/j.asjsur.2022.09.156↗
  11. Morphomolecular staging to improve stratification of patients with node-negative pancreatic cancer. Co-author DOI 10.1093/bjs/znac457↗
  12. A novel staging system derived from natural language processing of pathology reports to predict prognostic outcomes of pancreatic cancer: a retrospective cohor… Co-author DOI 10.1097/js9.0000000000000648↗
  13. A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-023-11181-x↗
  14. Systemic Immune-Inflammation Index After Neoadjuvant Therapy Predicts the Pathological Response in Patients with Resected Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-2856912/v1↗
  15. Systemic therapy and perioperative management improve the prognosis of pancreatic ductal adenocarcinoma: A retrospective cohort study of 2000 consecutive cases. Co-author DOI 10.1016/j.ijsu.2022.106786↗
  16. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. Co-author DOI 10.1038/s41467-022-29857-6↗
  17. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA. Co-author DOI 10.1186/s12916-022-02647-z↗
  18. Radiomics nomogram for the preoperative prediction of lymph node metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40644-021-00443-1↗
  19. Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Co-author DOI 10.1002/ctm2.520↗
  20. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08380-9↗
  21. Which Factors Are Associated with Positive Resection Margin in Pancreatic Ductal Adenocarcinoma for different surgical procedures? Results Based on a Standard … Co-author DOI 10.21203/rs.3.rs-111309/v2↗
  22. Risk Factors of Positive Resection Margin Differ in Pancreaticoduodenectomy and Distal Pancreatosplenectomy For Pancreatic Ductal Adenocarcinoma: A Study Based… Co-author DOI 10.21203/rs.3.rs-963631/v1↗
  23. The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients. Co-author DOI 10.3389/fonc.2021.717989↗
  24. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for… Co-author DOI 10.1016/j.surg.2020.02.013↗
  25. Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients. Co-author DOI 10.1038/s41416-019-0704-2↗
  26. Pros and Cons: High Proportion of Stromal Component Indicates Better Prognosis in Patients With Pancreatic Ductal Adenocarcinoma-A Research Based on the Evalua… Co-author DOI 10.3389/fonc.2020.01472↗
  27. Oncological and genetic factors impacting PDX model construction with NSG mice in pancreatic cancer. First author DOI 10.1096/fj.201800617r↗
  28. Relationship Between Radiomics and Risk of Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001404↗
  29. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: stu… Co-author DOI 10.1186/s13014-019-1254-8↗
  30. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer]. First author DOI 10.3760/cma.j.issn.0529-5815.2019.11.009↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gang Jin · 26 shared papers, 2019–2026 · strength 3.70
  2. Shiwei Guo · 25 shared papers, 2019–2026 · strength 3.57
  3. Xiaohan Shi · 23 shared papers, 2019–2026 · strength 3.22
  4. Kailian Zheng · 14 shared papers, 2019–2026 · strength 2.30
  5. Xiaoyi Yin · 13 shared papers, 2021–2026 · strength 2.16
  6. Xiongfei Xu · 10 shared papers, 2020–2026 · strength 1.53
  7. Guoxiao Zhang · 8 shared papers, 2021–2025 · strength 1.17
  8. Shuo Shen · 8 shared papers, 2019–2023 · strength 1.01
  9. Bo Li · 8 shared papers, 2020–2023 · strength 0.98
  10. Lingyu Zhu · 5 shared papers, 2023–2025 · strength 0.85
  11. Gang Li · 6 shared papers, 2021–2025 · strength 0.82
  12. Meilong Shi · 4 shared papers, 2025 · strength 0.77
  13. Bin Song · 4 shared papers, 2021–2025 · strength 0.58
  14. Hui Jiang · 5 shared papers, 2019–2023 · strength 0.58
  15. Zhuo Shao · 5 shared papers, 2019–2023 · strength 0.52
  16. Yunguang Li · 3 shared papers, 2022–2025 · strength 0.47
  17. Dong Gao · 3 shared papers, 2022–2025 · strength 0.47
  18. Chenming Ni · 3 shared papers, 2021–2023 · strength 0.43
  19. Hui Jiang · 3 shared papers, 2021–2023 · strength 0.43
  20. Wan Yee Lau · 3 shared papers, 2021–2023 · strength 0.43
  21. Jing Shen · 4 shared papers, 2019–2021 · strength 0.41
  22. Zhendong Fu · 2 shared papers, 2025 · strength 0.40
  23. Eric Tran · 2 shared papers, 2025–2026 · strength 0.39
  24. Gang Y Jin · 2 shared papers, 2023–2025 · strength 0.37
  25. Gang Jin · 2 shared papers, 2022–2025 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.